Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

By Alexandra Pecci • Aug. 9, 2022

Are Big Pharma CEOs earning their pay?

While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

By Kelly Bilodeau • Aug. 8, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

The ‘alarming’ spread of Monkeypox — by the numbers

With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

By Meagan Parrish • Aug. 8, 2022

Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.

By Michael Gibney • Aug. 4, 2022

Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

How these latest executive personnel changes are impacting the industry. 

By Karissa Waddick • Aug. 3, 2022

Taking probiotics where they’ve never gone before

How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

By Karissa Waddick • Aug. 2, 2022

‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients

EverythingALS aims to speed drug development through improved diagnostics.

By Kelly Bilodeau • Aug. 2, 2022

How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

By Kim Ribbink • Aug. 1, 2022

A glimpse inside Bristol Myers Squibb’s integration with Celgene

Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

By Meagan Parrish • Aug. 1, 2022

Personalized data could bring PhysIQ to the forefront of clinical trial evolution

The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

By Karissa Waddick • July 28, 2022

What’s next for Biogen? Here’s what executives are saying

A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

By Michael Gibney • July 27, 2022

Democrats think they've found a balance between drug innovation and pricing negotiation

A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

By Karissa Waddick • July 26, 2022

A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

By Michael Gibney • July 25, 2022

Behind Pfizer's new quest to target a 'transformation' in pharma

A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

By Kelly Bilodeau • July 25, 2022

With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

Both J&J and Novartis are making — or considering — big shifts in their fundamental company makeup.

By Michael Gibney • July 21, 2022

By the numbers: The rising danger of superbugs

A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.

By Karissa Waddick • July 20, 2022

Biotech R&D spending has skyrocketed, and so have opportunities for savings

With R&D costs on the rise, biotechs are embracing new strategies and technologies to make spending more efficient.

By Michael Gibney • July 19, 2022

Pfizer's former R&D head takes on drug pricing misconceptions in new book

John LaMattina has something to say about the industry — and he hopes patients are listening.

By Meagan Parrish • July 19, 2022

Making moves: Agios, BeiGene, Biocom California and more announce new key hires

The latest executive personnel changes from around the industry.

By Karissa Waddick • July 18, 2022

How digital health is changing the relationship between patients and health providers

The pandemic has forced the pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes

July 18, 2022

Janssen extends LGBTQ mental health outreach beyond Pride Month

The pharma giant’s ‘Depression looks like me’ campaign assembles a ‘one stop shop’ of resources to help combat high rates of severe depression in the LGBTQ community.

By Karissa Waddick • July 14, 2022

COVID won't evolve to become 'less deadly' — and RedHill is prepping for the long haul

RedHill Biopharma’s chief operating officer, Guy Goldberg, says the company’s oral COVID-19 therapy could still be needed on a global scale.

By Kim Ribbink • July 12, 2022

Behind the new topical treatment set to disrupt the psoriasis market

Phil Brown, Dermavant’s chief medical officer, discusses VTAMA — the first topical cream approved for psoriasis in 25 years.

By Kelly Bilodeau • July 11, 2022

Why a 'fundamental shift' in regulatory submissions is on the way

Deloitte's senior manager of R&D and regulatory practices explains how technology and strategy must converge to smooth out the bulky drug approval process.

By Michael Gibney • July 11, 2022

The CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing

Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.

By Meagan Parrish • July 7, 2022